Table 3.
Normal tissue distribution of radioactivity at selected times up to 48 h post-injection of 64Cu-NOTA-F(ab')2 * in non-tumor bearing Balb/c mice.
| Percent injected dose/g (%ID/g) |
|||||
|---|---|---|---|---|---|
| Tissue | 1 h | 3 h | 6 h | 24 h | 48 h |
| Blood | 13.6 ± 0.4 | 5.5 ± 1.6 | 1.6 ± 0.1 | 0.2 ± 0.0 | 0.2 ± 0.0 |
| Heart | 4.0 ± 0.2 | 3.6 ± 0.9 | 2.3 ± 0.2 | 1.0 ± 0.1 | 0.9 ± 0.1 |
| Lungs | 4.9 ± 0.4 | 4.1 ± 2.2 | 1.9 ± 0.1 | 1.3 ± 0.7 | 1.7 ± 1.2 |
| Liver | 6.9 ± 0.6 | 8.4 ± 2.3 | 6.3 ± 0.4 | 4.5 ± 0.6 | 4.7 ± 0.5 |
| Kidneys | 53.8 ± 1.2 | 81.0 ± 2.3 | 67.7 ± 5.9 | 53.6 ± 5.5 | 45.0 ± 4.0 |
| Spleen | 4.9 ± 0.6 | 7.4 ± 2.4 | 6.4 ± 0.5 | 3.6 ± 0.5 | 3.2 ± 0.5 |
| Stomach | 1.4 ± 0.1 | 1.6 ± 0.5 | 1.3 ± 0.1 | 0.7 ± 0.1 | 0.7 ± 0.1 |
| Intestines | 2.8 ± 0.6 | 2.1 ± 0.8 | 1.7 ± 0.2 | 1.0 ± 0.0 | 1.0 ± 0.1 |
| Muscle | 0.5 ± 0.1 | 0.5 ± 0.1 | 0.4 ± 0.2 | 0.2 ± 0.0 | 0.2 ± 0.0 |
| Bone | 2.2 ± 0.5 | 2.4 ± 1.3 | 2.2 ± 0.3 | 1.4 ± 0.2 | 1.0 ± 0.3 |
| Skin | 1.2 ± 0.1 | 1.8 ± 0.6 | 1.1 ± 0.3 | 0.4 ± 0.1 | 0.3 ± 0.0 |
| Brain | 0.4 ± 0.0 | 0.2 ± 0.1 | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.1 ± 0.0 |
| Ovaries | 1.6 ± 0.3 | 2.3 ± 0.7 | 1.2 ± 0.2 | 0.5 ± 0.1 | 0.5 ± 0.1 |
Values shown are mean ± SD (n = 4).
*
Mice were intravenously administered 2–4 MBq (50 µg) of 64Cu-NOTA-pertuzumab F(ab')2.